AYTU BioPharma
AYTU
3 hedge funds and large institutions have $907K invested in AYTU BioPharma in 2017 Q4 according to their latest regulatory filings, with 3 funds opening new positions, increasing their positions, reducing their positions, and closing their positions.
0% more ownership
Funds ownership: 0% → 0% (+0%)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
AC
Armistice Capital
New York
|
+$1.1M |
| 2 |
BA
Bard Associates
Chicago,
Illinois
|
+$95.5K |
| 3 |
HFM
Hartford Financial Management
Hartford,
Connecticut
|
+$23.9K |
Top Sellers
| Name | Holding | Trade Value |
Shares Change |
Change in Stake |
|
|---|---|---|---|---|---|
|
AC
1
Armistice Capital
New York
| $818K | +$1.1M | +92 | New |
|
|
BA
2
Bard Associates
Chicago,
Illinois
| $71K | +$95.5K | +8 | New |
|
|
HFM
3
Hartford Financial Management
Hartford,
Connecticut
| $15K | +$23.9K | +2 | New |
|
4
UBS Group
Zurich,
Switzerland
| $3K | – | – | – |
|
AYTU Hedge Fund Activity: Q4 2017 in Review
3 of the 4,409 institutional investors tracked by Wall St. Rank reported a position in AYTU BioPharma (AYTU) for Q4 2017, worth a combined $907K.
Buyers outnumbered sellers: 3 funds opened new AYTU positions and 0 closed out — a net gain of 3 holders — while 0 added to existing stakes and 0 trimmed.
The largest buyer was Armistice Capital, opening a new position worth an estimated $1.1M.
- 3 institutional investors held AYTU BioPharma (AYTU) as of Q4 2017, up from 0 in Q3 2017.
- Funds reported $907K of AYTU BioPharma stock for Q4 2017.
- 3 funds opened new AYTU BioPharma positions in Q4 2017 and 0 closed out, a net change of +3 holders.
- The largest AYTU BioPharma buyer in Q4 2017 was Armistice Capital, an estimated $1.1M added.
Based on aggregated 13F filings for Q4 2017.